| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Departments of 1 Surgery, 2 Ophtalmology, 3 Dermatology, 4 Immunology, and 5 Infectious Diseases and Microbiology, University of Pittsburgh; 6 Eye and Ear Institute; and 7 University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Requests for reprints: Pawel Kalinski, Department of Surgery, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Research Pavilion, Room 1.46b, 5117 Center Avenue, Pittsburgh, PA 15213-1863. Phone: 412-648-8957; Fax: 412-648-1077; E-mail: kalinskip{at}upmc.edu.
In contrast to the well-established efficacy of preventive vaccines, the effectiveness of therapeutic vaccines remains limited. To develop effective vaccination regimens against cancer, we have analyzed the effect of effector and memory CD8+ T cells on the ability of dendritic cells to mediate the immunologic and antitumor effects of vaccination. We show that in contrast to effector CD8+ T cells that kill antigen-carrying dendritic cells, IFN
-producing memory CD8+ T cells act as "helper" cells, supporting the ability of dendritic cells to produce interleukin-12 (IL-12) p70. Promoting the interaction of tumor antigen-carrying dendritic cells with memory-type "heterologous" (tumor-irrelevant) CD8+ T cells strongly enhances the IL-12p70-dependent immunogenic and therapeutic effects of vaccination in the animals bearing established tumors. Our data show that the suppressive and helper functions of CD8+ T cells are differentially expressed at different phases of CD8+ T-cell responses. Selective performance of helper functions by memory (in contrast to effector) CD8+ T cells helps to explain the phenomenon of immune memory and facilitates the design of effective therapeutic vaccines against cancer and chronic infections. [Cancer Res 2007;67(20):10012–8
This article has been cited by other articles:
![]() |
K. L. Wong, L. F. M. Tang, F. C. Lew, H. S. K. Wong, Y. L. Chua, P. A. MacAry, and D. M. Kemeny CD44high Memory CD8 T Cells Synergize with CpG DNA to Activate Dendritic Cell IL-12p70 Production J. Immunol., July 1, 2009; 183(1): 41 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zhao, A. Song, R. Haque, F. Lei, L. Weiler, X. Xiong, Y. Wu, M. Croft, and J. Song Cooperation between Molecular Targets of Costimulation in Promoting T Cell Persistence and Tumor Regression J. Immunol., June 1, 2009; 182(11): 6744 - 6752. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fujita, X. Zhu, R. Ueda, K. Sasaki, G. Kohanbash, E. R. Kastenhuber, H. A. McDonald, G. A. Gibson, S. C. Watkins, R. Muthuswamy, et al. Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells--Significant Roles of CXCL10 Cancer Res., February 15, 2009; 69(4): 1587 - 1595. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Watchmaker, J. A. Urban, E. Berk, Y. Nakamura, R. B. Mailliard, S. C. Watkins, S. M. van Ham, and P. Kalinski Memory CD8+ T Cells Protect Dendritic Cells from CTL Killing J. Immunol., March 15, 2008; 180(6): 3857 - 3865. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |